The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Monoclonal Antibodies in Cancer Therapy
Open accessAbstract
Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have led to the development of new cancer treatment strategies that will have major impacts on cancer care. This review focuses on the known mechanisms of action, current clinical applications for the treatment of cancer, and mechanisms of resistance of monoclonal antibody therapy. We further discuss how monoclonal antibody-based strategies have moved towards enhancing anti-tumor immune responses by targeting immune cells instead of tumor antigens as well as some of the current combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 1×
“NK cells are the main effector type that mediate ADCC; however other myeloid types such as monocytes, macrophages, neutrophils, eosinophils, and dendritic cells are also capable [26].”
BackgroundInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“w re the firs to demonstrate that ADCC was an essential contributor to the in vivo activity of trastuz mab and rituximab [31].”
BackgroundMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“CTLA-4 is mainly expressed by Treg cells but also becomes upregulated on activated T cells where it then outcompetes for binding of the costimulatory ligands CD80 and CD86 [77].”
BackgroundShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Self-citationHargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Furthermore, both genotypes of FcγRIIA and FcγRIIIA associated with higher affinity for Fc were robust predictors for better survival in colorectal cancer patients treated with cetuximab and metastatic breast cancer patients treated with trastuzumab respectively [40,41].”
BackgroundAntibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V, Guyre, P. M., Coleman, K., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren
(1890) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1207589 · Cited by 643
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 626
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · cited 1×
“In humans, bothFcγRIIA and FcγRIIIA are polymorphic, with certain genotypes coding for FcγRs with higher affinity for IgG1 and therefore stronger ADCC activity [35,36].”
BackgroundGennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., Jerusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 470
Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules
de Saint Basile, G., Ménasché, G., & Fischer, A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2803 · Cited by 446
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
Nijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393
Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111781 · Cited by 387
Cytotoxicity mediated by human Fc receptors for IgG
Fanger, M. W., Shen, L., Graziano, R. F., & Guyre, P. M. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90234-x · Cited by 371
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
Contact-Induced Cytotoxicity by Lymphoid Cells Containing Foreign Isoantigens
Möller, E. (1965) · Science · doi:10.1126/science.147.3660.873 · Cited by 327
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Rech, A. J., & Vonderheide, R. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04939.x · Cited by 289
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., et al. (2007) · Blood · doi:10.1182/blood-2007-01-070656 · Cited by 282
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 275
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 240
Czuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., & Hernandez-Ilizaliturri, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1254 · Cited by 232
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Chandarlapaty, S., Sakr, R. A., Giri, D., Patil, S., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N., Hudis, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1785 · Cited by 227
Minard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C. M., Hamaguchi, Y., Haas, K. M., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-01-135160 · Cited by 218
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213
Clinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 188
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
Self-citationJazirehi, A. R., Vega, M. I., & Bonavida, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2184 · Cited by 167
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Moxetumomab Pasudotox: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-1000-9 · Cited by 162
Racila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
Oliveras‐Ferraros, C., Corominas-Faja, B., Cufí, S., Vázquez‐Martín, A., Martín-Castillo, B., Iglesias, J. M., López‐Bonet, E., Martín, Á. G., & Menéndez, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22225 · Cited by 156
Wu, Y. L., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E. C., Balderes, P. J., Jimenez, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0831 · Cited by 152
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Xu, F., Sunderland, A., Zhou, Y., Schulick, R. D., Edil, B. H., & Zhu, Y. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2031-x · Cited by 152
New checkpoints in cancer immunotherapy
Ni, L., & Dong, C. (2017) · Immunological Reviews · doi:10.1111/imr.12524 · Cited by 149
[On the development of immunity to diphtheria and tetanus in animals].
Behring, & Kitasato (1965) · PubMed · Cited by 142
Hubert, P., Heitzmann, A., Viel, S., Nicolas, A., Sastre‐Garau, X., Oppezzo, P., Pritsch, O., Osinaga, E., & Amigorena, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4222 · Cited by 132
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
de Haij, S., Jansen, J. H. M., Boross, P., Beurskens, F. J. M., Bakema, J. E., Bos, D. L., Martens, A. C., Verbeek, J. S., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4109 · Cited by 130
Human Tumor Antigens Yesterday, Today, and Tomorrow
Finn, O. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0112 · Cited by 126
Griguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 124
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 120
Benavente, S., Huang, S., Armstrong, E. A., Chi, A., Hsu, K.-T., Wheeler, D. L., & Harari, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2068 · Cited by 106
Strategies to target HER2/neu overexpression for cancer therapy
Chen, J., Lan, K., & Hung, M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00040-2 · Cited by 102
Krupitskaya, Y., & Wakelee, H. A. (2009) · PubMed · Cited by 98
Role of Fcγ receptors in cancer and infectious disease
Wallace, P. K., Howell, A. L., & Fanger, M. W. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.6.816 · Cited by 90
Plasma Cellular Reaction and its Relation to the Formation of Antibodies in vitro
Fagraeus, A. (1947) · Nature · doi:10.1038/159499a0 · Cited by 88
[32] Production and properties of chimeric antibody molecules
Shin, S.-U., & Morrison, S. L. (1989) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(89)78034-4 · Cited by 87
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Braig, F., Kriegs, M., Voigtlaender, M., Habel, B., Grob, T. J., Biskup, K., Blanchard, V., Sack, M., Thalhammer, A., Batalla, I. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0754 · Cited by 87
Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 86
Liu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 83
Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A. A., Fertig, E. J., Howard, J. D., Marković, A. K., Bedi, A., Ravi, R. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1686 · Cited by 78
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
Sickmier, E. A., Kurzeja, R. J. M., Michelsen, K., Vazir, M., Yang, E., & Tasker, A. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163366 · Cited by 76
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
Corraliza-Gorjón, I., Somovilla-Crespo, B., Santamaría, S. S., García‐Sanz, J. A., & Kremer, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01804 · Cited by 74
Analyzing Antibody–Fc-Receptor Interactions
Nimmerjahn, F., & Ravetch, J. V. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-570-1_9 · Cited by 72
Abdin, S. M., Zaher, D. M., Arafa, E. A., & Omar, H. A. (2018) · Cancers · doi:10.3390/cancers10020032 · Cited by 71
Kang, C. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000125 · Cited by 70
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 70
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 70
Schmitz, S., Bindea, G., Albu, R. I., Mlecnik, B., & Machiels, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5924 · Cited by 68
Shen, J., Vil, M. D., Prewett, M. C., Damoci, C., Zhang, H., Li, H., Jimenez, X., Deevi, D. S., Iacolina, M. D., Kayas, A., et al. (2009) · Neoplasia · doi:10.1593/neo.09278 · Cited by 67
Seo, Y., Ishii, Y., Ochiai, H., Fukuda, K., Akimoto, S., Hayashida, T., Okabayashi, K., Tsuruta, M., Hasegawa, H., & Kitagawa, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3077 · Cited by 67
Antibody-Based Immunotoxins for the Treatment of Cancer
Becker, N., & Benhar, I. (2012) · Antibodies · doi:10.3390/antib1010039 · Cited by 63
Shi, Y., Fan, X., Meng, W., Deng, H., Zhang, N., & An, Z. (2014) · Breast Cancer Research · doi:10.1186/bcr3637 · Cited by 61
Siebert, N., Jensen, C., Troschke‐Meurer, S., Zumpe, M., Jüttner, M., Ehlert, K., Kietz, S., Müller, I., & Lode, H. N. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235108 · Cited by 59
A Mechanism of Resistance to Antibody-Targeted Immune Attack
Aldeghaither, D. S., Zahavi, D. J., Murray, J. C., Fertig, E. J., Graham, G. T., Zhang, Y., O’Connell, A., Ma, J., Jablonski, S. A., & Weiner, L. M. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0266 · Cited by 59
Self-citationA cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions
Grütter, C., Wilkinson, T. C. I., Turner, R., Podichetty, S., Finch, D. K., McCourt, M., Loning, S., Jermutus, L., & Grütter, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807200106 · Cited by 56
Siu, L. L., Steeghs, N., Meniawy, T. M., Joerger, M., Spratlin, J. L., Rottey, S., Nagrial, A. M., Cooper, A. J., Meier, R., Guan, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.104 · Cited by 55
Evans, M. K., Sauer, S. J., Nath, S., Robinson, T. J., Morse, M. A., & Devi, G. R. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.412 · Cited by 53
Boero, S., Morabito, A., Banelli, B., Cardinali, B., Dozin, B., Lunardi, G., Piccioli, P., Lastraioli, S., Carosio, R., Salvi, S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0680-0 · Cited by 52
Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells
Capuano, C., Romanelli, M., Pighi, C., Cimino, G., Rago, A., Molfetta, R., Paolini, R., Santoni, A., & Galandrini, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0781 · Cited by 51
Kimura, I., Kitahara, H., Ooi, K., Kato, K., NOGUCHI, N., Yoshizawa, K., Nakamura, H., & Kawashiri, S. (2015) · Oncology Letters · doi:10.3892/ol.2015.3833 · Cited by 48
Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., Queralt, B., Báez, L., Guardeño, R., Hernández‐Yagüe, X., Martin‐Castillo, B., Brunet, J., & Menendez, J. A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22952 · Cited by 47
Korman, A. J., Chen, B., Wang, C., Wu, L., Cardarelli, P. M., & Selby, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.supp.48.37 · Cited by 47
Cheng, H., Fertig, E. J., Ozawa, H., Hatakeyama, H., Howard, J. D., Pérez, J., Considine, M., Thakar, M., Ranaweera, R. S., Krigsfeld, G. S., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1056418 · Cited by 45
Nakadate, Y., Kodera, Y., Kitamura, Y., Shirasawa, S., Tachibana, T., Tamura, T., & Koizumi, F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28550 · Cited by 45
slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP
Vermi, W., Micheletti, A., Finotti, G., Tecchio, C., Calzetti, F., Costa, S. E., Bugatti, M., Calza, S., Agostinelli, C., Pileri, S. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2344 · Cited by 41
Hsu, D. S., Hwang, W., Yuh, C., Chu, C.-H., Ho, Y.-H., Chen, P.-B., Lin, H.-S., Lin, H., Wu, S.-P., Lin, C.-Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1955 · Cited by 36
Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
Kong, X., Zhang, K., Wang, X., Yang, X. C., Li, Y., Zhai, J., Xing, Z., Qi, Y., Gao, R., Feng, X., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s194137 · Cited by 35
Antibody‐dependent Cellular Cytotoxicity ( ADCC )
Teillaud, J. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0000498.pub2 · Cited by 29
Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
Ahmad, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_10 · Cited by 28
Xue, F., Liu, Y., Chu, H., Wen, Y., Yan, L., Tang, Q., Xiao, E., Zhang, D., & Zhang, H. (2016) · PubMed · Cited by 22
Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies
Lee, S. C., López‐Albaitero, A., & Ferris, R. L. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0023-5 · Cited by 21
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 16
Cuyàs, E., Queralt, B., Martín-Castillo, B., Bosch‐Barrera, J., & Menéndez, J. A. (2017) · Oncology Reports · doi:10.3892/or.2017.5682 · Cited by 14
Cited by
Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, D. J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., et al. (2022) · Cancers · doi:10.3390/cancers14071732 · Cited by 920
The past, present, and future of antibiotics
Cook, M. A., & Wright, G. D. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7793 · Cited by 652
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 315
Metadata
- Authors
- Zahavi, D., & Weiner, L.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2020-07-20
- Volume
- 9
- Issue
- 3
- Pages
- 34
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W3042291772
- Cited by
- 831
- References
- 135
- FWCI
- 40.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.